| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2021 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DESIGN THERAPEUTICS INC | 8 | Q3 2023 | 68.1% |
| EFFECTOR THERAPEUTICS INC | 8 | Q3 2023 | 31.9% |
| ARCELLX INC. | 7 | Q3 2023 | 72.6% |
| NKARTA INC. | 6 | Q3 2023 | 8.0% |
| ARS PHARMACEUTICALS INC | 4 | Q3 2023 | 11.6% |
| MINERALYS THERAPEUTICS INC | 3 | Q3 2023 | 13.2% |
View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-10 |
| 13F-HR/A | 2023-05-19 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-08 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-14 |
View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.